File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: New horizons in the management of glioblastoma multiforme: The end of the beginning?

TitleNew horizons in the management of glioblastoma multiforme: The end of the beginning?
Authors
KeywordsAngiogenesis Inhibitors
Brain Neoplasms
Chemotherapy, Adjuvant
Glioblastoma
Neoplasm Recurrent, Local
Issue Date2010
PublisherScientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/
Citation
Journal Of The Hong Kong College Of Radiologists, 2010, v. 13 n. 3 SUPPL., p. 29-32 How to Cite?
AbstractGlioblastoma multiforme is a highly invasive and aggressive brain tumour. It is the most commonly seen glioma with fast-growing features, being a devastating disease with no clear causation and no means of early detection. Less than 10% of glioblastoma multiforme patients survive more than 5 years after diagnosis. Current standard treatment includes maximal safe surgical resection and adjuvant concurrent chemo-irradiation with temozolomide followed by adjuvant temozolomide. Resistance to standard therapy still develops however, suggesting that glioblastoma multiforme cells are capable of switching their dependency from one signalling pathway to an alternative. Glioblastoma multiforme is a highly vascularised disease, in which angiogenesis plays an important role contributing to its progression and deadly course. Recently, therapies with agents targeting the vascular endothelial growth factor and vascular endothelial growth factor receptor have shown clinical benefits in patients with recurrent glioblastoma multiforme. It is indeed important to identify novel angiogenic factors that play essential roles in tumour angiogenesis and glioblastoma multiforme progression. This paper gives an overview of the management of glioblastoma multiforme including new treatments that are available, touches upon potential new therapies based on the aforesaid understanding, and discusses the promise and challenges of achieving better outcomes in this patient group. © 2010 Hong Kong College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/150834
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorTsang, Jen_US
dc.date.accessioned2012-06-26T06:11:43Z-
dc.date.available2012-06-26T06:11:43Z-
dc.date.issued2010en_US
dc.identifier.citationJournal Of The Hong Kong College Of Radiologists, 2010, v. 13 n. 3 SUPPL., p. 29-32en_US
dc.identifier.issn1029-5097en_US
dc.identifier.urihttp://hdl.handle.net/10722/150834-
dc.description.abstractGlioblastoma multiforme is a highly invasive and aggressive brain tumour. It is the most commonly seen glioma with fast-growing features, being a devastating disease with no clear causation and no means of early detection. Less than 10% of glioblastoma multiforme patients survive more than 5 years after diagnosis. Current standard treatment includes maximal safe surgical resection and adjuvant concurrent chemo-irradiation with temozolomide followed by adjuvant temozolomide. Resistance to standard therapy still develops however, suggesting that glioblastoma multiforme cells are capable of switching their dependency from one signalling pathway to an alternative. Glioblastoma multiforme is a highly vascularised disease, in which angiogenesis plays an important role contributing to its progression and deadly course. Recently, therapies with agents targeting the vascular endothelial growth factor and vascular endothelial growth factor receptor have shown clinical benefits in patients with recurrent glioblastoma multiforme. It is indeed important to identify novel angiogenic factors that play essential roles in tumour angiogenesis and glioblastoma multiforme progression. This paper gives an overview of the management of glioblastoma multiforme including new treatments that are available, touches upon potential new therapies based on the aforesaid understanding, and discusses the promise and challenges of achieving better outcomes in this patient group. © 2010 Hong Kong College of Radiologists.en_US
dc.languageengen_US
dc.publisherScientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/en_US
dc.relation.ispartofJournal of the Hong Kong College of Radiologistsen_US
dc.subjectAngiogenesis Inhibitorsen_US
dc.subjectBrain Neoplasmsen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectGlioblastomaen_US
dc.subjectNeoplasm Recurrent, Localen_US
dc.titleNew horizons in the management of glioblastoma multiforme: The end of the beginning?en_US
dc.typeArticleen_US
dc.identifier.emailTsang, J:jwhtsang@hku.hken_US
dc.identifier.authorityTsang, J=rp00278en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-79952063648en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952063648&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume13en_US
dc.identifier.issue3 SUPPL.en_US
dc.identifier.spage29en_US
dc.identifier.epage32en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridTsang, J=35141929400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats